The soy plant, soy milk and soy flour are all commonly used in foods and drinks.
These ingredients are derived from the soybean, and it is the same type of crop that gives us beans, corn and rice.
But soy is made from an even older plant, the soy millet, which was domesticated by Europeans, and later domesticated in China, the world’s largest producer of soybeans.
The soybeans that are grown in China are far more genetically diverse, and contain more protein, iron, manganese and zinc than the crops grown in Africa.
So it’s a bit surprising that the link between soy and breast and colorectal cancers in men has been so poorly understood.
We knew that men with high concentrations of the protein-degrading chemicals in soy products were twice as likely to develop breast cancer as those with a normal diet, says Professor David Moberg of the University of Western Australia in Perth, who led the study.
However, the link was not yet clear in men who were also at high risk for coloreclastis, a rare form of the disease.
This means that it’s important to know the exact cause of these cancers, so we can figure out whether a particular soy product is safe for people who are at high-risk, says Dr David Hallett, from the Australian Cancer Society.
We need to understand the genetic changes that are occurring in these soybean plants, so if we can identify those that are causing these cancers in our men, we can work out what might be causing them in other men.
It’s possible that the cancer risk of soy products is linked to other soy ingredients, he says.
But the research team looked at the genetic makeup of soybean genes and found that there were genes that were different in men than in women.
The genes in question were called TGF-β (trimethylglycine-G-protein), and they are the same proteins that are produced by all plants and animals.
They are involved in a wide range of processes in the body, from hormone production to energy production.TGF-beta is produced by a group of genes called the TRP family.
They work with the body to regulate hormones and make the proteins needed for the body’s normal functioning.
Treatment with TRP inhibitors like imipramine, a cancer drug, can reduce tumour growth in laboratory animals, but in humans they can cause an increase in tumour size.
So the researchers found that the genes that control TGFB are also involved in breast cancer.
The TRP gene is involved in regulating breast cancer growth in miceThe team found that TGF genes are involved both in breast and prostate cancer.
The TRP genes are also part of the same genes that are responsible for breast cancer progression in mice, says Halleitt.
This suggests that the TGF gene may be the cause of both types of cancer in humans, he adds.
The team looked for genetic differences in the genes in the TRPMG family of genes that determine the proteins produced by the human TRP.
The gene that controls TRPMF1 is known to be involved in cancer in both men and women, but the gene that regulates TRPMP1 is less clear.
The researchers found a link between TRPM1 and breast tumors in miceA number of studies have suggested that TRPM2 might be involved with breast cancer, but no one knew whether the gene involved was the same as the one that controls breast cancer development in mice.
So the researchers looked for differences in a gene called TRPM-2 that controls the proteins that the TRPA1 receptor, which is also involved with TRPM and breast cancers, makes in mice and rats.
They found that TRP-2 controls the TRPU2 protein.
This is the protein that binds to the TRPC-1 protein and makes the TRpC-1 receptor.
In humans, this receptor is involved with inflammation and pain, so it’s likely to be a gene that is involved, says the team.
The same is true for TRP2, says Moberge.
The research team also looked at how the genes of the TRPG family of proteins that regulate breast and the prostate also affected breast cancer risk.
These genes are known to affect cancer in mice as well, but it’s not known whether these are involved.
But they showed that the differences between the genes involved in the cancers could be down to different levels of the risk factors that increase risk.
They found that when the researchers put TRP3 in mice that were exposed to TRPM3, the mice had significantly more tumours in the testes.
But when the team put TRPA3 into the mice that had not been exposed to the drug, the animals were still protected from breast cancer and prostate cancers.
There was a clear association between the levels of TRP receptors and tumour formation in both tumours, but this was